Analysis of Sequence and Copy Number Variants in Canadian Patient Cohort With Familial Cancer Syndromes Using a Unique Next Generation Sequencing Based Approach.
breast cancer
colorectal cancer
copy number variants
familial cancer syndromes
next generation sequencing
Journal
Frontiers in genetics
ISSN: 1664-8021
Titre abrégé: Front Genet
Pays: Switzerland
ID NLM: 101560621
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
04
2021
accepted:
07
06
2021
entrez:
30
7
2021
pubmed:
31
7
2021
medline:
31
7
2021
Statut:
epublish
Résumé
Hereditary cancer predisposition syndromes account for approximately 10% of cancer cases. Next generation sequencing (NGS) based multi-gene targeted panels is now a frontline approach to identify pathogenic mutations in cancer predisposition genes in high-risk families. Recent evolvement of NGS technologies have allowed simultaneous detection of sequence and copy number variants (CNVs) using a single platform. In this study, we have analyzed frequency and nature of sequence variants and CNVs, in a Canadian cohort of patients, suspected with hereditary cancer syndrome, referred for genetic testing following specific genetic testing guidelines based on patient's personal and/or family history of cancer. A 2870 patients were subjected to a single NGS based multi-gene targeted hereditary cancer panel testing algorithm to identify sequence variants and CNVs in cancer predisposition genes at our reference laboratory in Southwestern Ontario. CNVs identified by NGS were confirmed by alternative techniques like Multiplex ligation-dependent probe amplification (MLPA). A 15% (431/2870) patients had a pathogenic variant and 36% (1032/2870) had a variant of unknown significance (VUS), in a cancer susceptibility gene. A total of 287 unique pathogenic variant were identified, out of which 23 (8%) were novel. CNVs identified by NGS based approach accounted for 9.5% (27/287) of pathogenic variants, confirmed by alternate techniques with high accuracy. This study emphasizes the utility of NGS based targeted testing approach to identify both sequence and CNVs in patients suspected with hereditary cancer syndromes in clinical setting and expands the mutational spectrum of high and moderate penetrance cancer predisposition genes.
Sections du résumé
BACKGROUND
BACKGROUND
Hereditary cancer predisposition syndromes account for approximately 10% of cancer cases. Next generation sequencing (NGS) based multi-gene targeted panels is now a frontline approach to identify pathogenic mutations in cancer predisposition genes in high-risk families. Recent evolvement of NGS technologies have allowed simultaneous detection of sequence and copy number variants (CNVs) using a single platform. In this study, we have analyzed frequency and nature of sequence variants and CNVs, in a Canadian cohort of patients, suspected with hereditary cancer syndrome, referred for genetic testing following specific genetic testing guidelines based on patient's personal and/or family history of cancer.
METHODS
METHODS
A 2870 patients were subjected to a single NGS based multi-gene targeted hereditary cancer panel testing algorithm to identify sequence variants and CNVs in cancer predisposition genes at our reference laboratory in Southwestern Ontario. CNVs identified by NGS were confirmed by alternative techniques like Multiplex ligation-dependent probe amplification (MLPA).
RESULTS
RESULTS
A 15% (431/2870) patients had a pathogenic variant and 36% (1032/2870) had a variant of unknown significance (VUS), in a cancer susceptibility gene. A total of 287 unique pathogenic variant were identified, out of which 23 (8%) were novel. CNVs identified by NGS based approach accounted for 9.5% (27/287) of pathogenic variants, confirmed by alternate techniques with high accuracy.
CONCLUSION
CONCLUSIONS
This study emphasizes the utility of NGS based targeted testing approach to identify both sequence and CNVs in patients suspected with hereditary cancer syndromes in clinical setting and expands the mutational spectrum of high and moderate penetrance cancer predisposition genes.
Identifiants
pubmed: 34326862
doi: 10.3389/fgene.2021.698595
pmc: PMC8314385
doi:
Types de publication
Journal Article
Langues
eng
Pagination
698595Informations de copyright
Copyright © 2021 Bhai, Levy, Rooney, Carere, Reilly, Kerkhof, Volodarsky, Stuart, Kadour, Panabaker, Schenkel, Lin, Ainsworth and Sadikovic.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Res Treat. 2020 Jul;52(3):697-713
pubmed: 32019277
Nat Genet. 1998 Sep;20(1):13-4
pubmed: 9731522
J Natl Cancer Inst. 2005 Jun 1;97(11):813-22
pubmed: 15928302
Acta Biomed. 2019 Jan 15;89(4):463-469
pubmed: 30657113
BMC Bioinformatics. 2013;14 Suppl 11:S1
pubmed: 24564169
J Clin Oncol. 2020 May 1;38(13):1409-1418
pubmed: 32125938
Cold Spring Harb Mol Case Stud. 2017 Nov 21;3(6):
pubmed: 29162654
J Mol Diagn. 2017 Nov;19(6):905-920
pubmed: 28818680
Genet Med. 2018 Oct;20(10):1167-1174
pubmed: 29345684
Nat Genet. 1998 Sep;20(1):62-5
pubmed: 9731533
Ann Oncol. 2011 Sep;22 Suppl 6:vi31-4
pubmed: 21908500
Nat Genet. 2007 Feb;39(2):165-7
pubmed: 17200668
Genet Med. 2020 Feb;22(2):407-415
pubmed: 31406321
BMC Med Genet. 2007 Jun 11;8:32
pubmed: 17561994
BMC Med Genet. 2019 May 7;20(1):75
pubmed: 31064327
BMC Med Genomics. 2019 Oct 17;12(1):138
pubmed: 31623605
JAMA Oncol. 2021 Feb 1;7(2):230-237
pubmed: 33126242
Open Access Bioinformatics. 2010 Feb;2010(2):1-9
pubmed: 22022206
Breast Cancer Res Treat. 2020 Jun;181(2):465-473
pubmed: 32318955
Genet Med. 2019 Jul;21(7):1507-1516
pubmed: 30523343
J Mol Diagn. 2016 Sep;18(5):657-667
pubmed: 27376475
Hum Mutat. 2016 Jun;37(6):564-9
pubmed: 26931183
J Natl Cancer Inst. 2018 Jul 1;110(7):714-725
pubmed: 29361001
Front Oncol. 2019 Dec 20;9:1429
pubmed: 31921681
Genet Med. 2016 Aug;18(8):823-32
pubmed: 26681312
JAMA Oncol. 2019 Oct 3;:
pubmed: 31580391
J Med Genet. 2021 Apr;58(4):284-288
pubmed: 32376792
Genet Med. 2019 Jul;21(7):1497-1506
pubmed: 30504931
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Breast Cancer Res Treat. 2009 May;115(2):315-23
pubmed: 18546071
Cancer Genet. 2017 Dec;218-219:58-68
pubmed: 29153097
Int J Cancer. 2017 Jul 1;141(1):129-142
pubmed: 28294317
Breast Cancer Res Treat. 2018 Jan;167(2):417-423
pubmed: 29039119
BMC Cancer. 2019 Jun 3;19(1):535
pubmed: 31159747
Int J Cancer. 2019 Mar 1;144(5):1195-1204
pubmed: 30175445
J Mol Diagn. 2019 Jul;21(4):646-657
pubmed: 31201024